147 related articles for article (PubMed ID: 28927061)
1. 5FU resistance caused by reduced fluoro-deoxyuridine monophosphate and its reversal using deoxyuridine.
Mori R; Futamura M; Tanahashi T; Tanaka Y; Matsuhashi N; Yamaguchi K; Yoshida K
Oncol Lett; 2017 Sep; 14(3):3162-3168. PubMed ID: 28927061
[TBL] [Abstract][Full Text] [Related]
2. The inhibition of thymidine phosphorylase can reverse acquired 5FU-resistance in gastric cancer cells.
Mori R; Yoshida K; Futamura M; Suetsugu T; Shizu K; Tanahashi T; Tanaka Y; Matsuhashi N; Yamaguchi K
Gastric Cancer; 2019 May; 22(3):497-505. PubMed ID: 30276573
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines.
Suetsugu T; Mori R; Futamura M; Fukada M; Tanaka H; Yasufuku I; Sato Y; Iwata Y; Imai T; Imai H; Tanaka Y; Okumura N; Matsuhashi N; Takahashi T; Yoshida K
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649846
[TBL] [Abstract][Full Text] [Related]
4. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism.
Peters GJ; Backus HH; Freemantle S; van Triest B; Codacci-Pisanelli G; van der Wilt CL; Smid K; Lunec J; Calvert AH; Marsh S; McLeod HL; Bloemena E; Meijer S; Jansen G; van Groeningen CJ; Pinedo HM
Biochim Biophys Acta; 2002 Jul; 1587(2-3):194-205. PubMed ID: 12084461
[TBL] [Abstract][Full Text] [Related]
5. Trifluridine/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory cells with high thymidylate synthase expression.
Matsuoka K; Nakagawa F; Kobunai T; Takechi T
Oncotarget; 2018 Mar; 9(17):13438-13450. PubMed ID: 29568368
[TBL] [Abstract][Full Text] [Related]
6. The mechanism underlying resistance to 5-fluorouracil and its reversal by the inhibition of thymidine phosphorylase in breast cancer cells.
Mori R; Ukai J; Tokumaru Y; Niwa Y; Futamura M
Oncol Lett; 2022 Sep; 24(3):311. PubMed ID: 35949616
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition.
Bijnsdorp IV; Comijn EM; Padron JM; Gmeiner WH; Peters GJ
Oncol Rep; 2007 Jul; 18(1):287-91. PubMed ID: 17549381
[TBL] [Abstract][Full Text] [Related]
8. Decreased FANCJ caused by 5FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells.
Mori R; Yoshida K; Tanahashi T; Yawata K; Kato J; Okumura N; Tsutani Y; Okada M; Oue N; Yasui W
Gastric Cancer; 2013 Jul; 16(3):345-54. PubMed ID: 22968820
[TBL] [Abstract][Full Text] [Related]
9. Decreased orotate phosphoribosyltransferase activity produces 5-fluorouracil resistance in a human gastric cancer cell line.
Tsutani Y; Yoshida K; Sanada Y; Wada Y; Konishi K; Fukushima M; Okada M
Oncol Rep; 2008 Dec; 20(6):1545-51. PubMed ID: 19020740
[TBL] [Abstract][Full Text] [Related]
10. A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase I-DNA complexes.
Liao ZY; Sordet O; Zhang HL; Kohlhagen G; Antony S; Gmeiner WH; Pommier Y
Cancer Res; 2005 Jun; 65(11):4844-51. PubMed ID: 15930305
[TBL] [Abstract][Full Text] [Related]
11. Development, characterization and application of an antibody against 5-fluoro-2'deoxyuridine-5'monophosphate, the active metabolite of 5-fluorouracil.
Peters GJ; Laurensse E; Steinbusch HW; De Vente J; Smid K; Van der Wilt CL; Pinedo HM
Anticancer Res; 1993; 13(4):835-9. PubMed ID: 8352551
[TBL] [Abstract][Full Text] [Related]
12. Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells.
Inaba M; Mitsuhashi J; Sawada H; Miike N; Naoe Y; Daimon A; Koizumi K; Tsujimoto H; Fukushima M
Jpn J Cancer Res; 1996 Feb; 87(2):212-20. PubMed ID: 8609072
[TBL] [Abstract][Full Text] [Related]
13. Increased cytotoxicity and decreased in vivo toxicity of FdUMP[10] relative to 5-FU.
Liu J; Skradis A; Kolar C; Kolath J; Anderson J; Lawson T; Talmadge J; Gmeiner WH
Nucleosides Nucleotides; 1999 Aug; 18(8):1789-802. PubMed ID: 10478484
[TBL] [Abstract][Full Text] [Related]
14. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
[TBL] [Abstract][Full Text] [Related]
15. Immunological quantitation of thymidylate synthase-FdUMP-5,10-methylenetetrahydrofolate ternary complex with the monoclonal antibody TS 106.
Drake JC; Allegra CJ; Johnston PG
Anticancer Drugs; 1993 Aug; 4(4):431-5. PubMed ID: 8400344
[TBL] [Abstract][Full Text] [Related]
16. Fluorouracil: biochemistry and pharmacology.
Pinedo HM; Peters GF
J Clin Oncol; 1988 Oct; 6(10):1653-64. PubMed ID: 3049954
[TBL] [Abstract][Full Text] [Related]
17. A method for the determination of total, free, and 5-fluorodeoxyuridylate-bound thymidylate synthase in cell extracts.
Fernandes DJ; Cranford SK
Anal Biochem; 1984 Nov; 142(2):378-85. PubMed ID: 6241433
[TBL] [Abstract][Full Text] [Related]
18. Regulation of 5-fluorodeoxyuridine monophosphate-thymidylate synthase ternary complex levels by autophagy confers resistance to 5-fluorouracil.
Nishizawa N; Kurasaka C; Ogino Y; Sato A
FASEB Bioadv; 2023 Jan; 5(1):43-51. PubMed ID: 36643896
[TBL] [Abstract][Full Text] [Related]
19. Development of modified siRNA molecules incorporating 5-fluoro-2'-deoxyuridine residues to enhance cytotoxicity.
Wu SY; Chen TM; Gmeiner WH; Chu E; Schmitz JC
Nucleic Acids Res; 2013 Apr; 41(8):4650-9. PubMed ID: 23449220
[TBL] [Abstract][Full Text] [Related]
20. Comparative cytotoxicity of folate-based inhibitors of thymidylate synthase and 5-fluorouracil +/- leucovorin in MGH-U1 cells.
Erlichman C; Mitrovski B
Cancer Chemother Pharmacol; 1994; 34(1):51-6. PubMed ID: 8174202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
